Mixed Hormone Receptor (ER+/PR- Or ER-/PR+) Breast Cancer
By A Mystery Man Writer
Description
Detailed information on mixed hormone receptor (ER+/PR- or ER-/PR+) breast cancer prognosis, based on the latest scientific studies.
Breast tumor subtypes defined by expression of estrogen receptor (ER)
Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance
Heterogeneity in hormone-dependent breast cancer and therapy: Steroid hormones, HER2, melanoma antigens, and cannabinoid receptors - ScienceDirect
Cancers, Free Full-Text
Overall survival of patients stratified by estrogen receptor (ER)
Frontiers Prognostic Relevance of Estrogen Receptor Status in Circulating Tumor Cells in Breast Cancer Patients Treated With Endocrine Therapy
Crosstalk between ER and HER family receptors. ER, estrogen receptor;
Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
Updates in endocrine therapy for metastatic breast cancer
Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
Triple Negative Breast Cancer—Review of Current and Emerging Therapeutic Strategies - touchONCOLOGY
Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating ESR1 Mutation
from
per adult (price varies by group size)